EHA 2017 | MOR208: an effective drug for the treatment of CLL
Wojciech Jurczak
• 22 Jun 2017
Wojciech Jurczak, MD, PhD, from Jagiellonian University, Krakow, Poland, discusses the potential of administering single-agent MOR208, an anti-CD19 antibody, to treat chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (BCL). Here, he explains that the MOR208 has proven to be very effective in treating CLL but less effective in BCL, although it does overall represent a good candidate for combination therapy, possibly with an anti-PD1 agent. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
